Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ.

J Natl Cancer Inst. 2003 Jun 18;95(12):868-78.

PMID:
12813170
2.
3.

Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam.

van der Cruijsen-Koeter IW, van der Kwast TH, Schröder FH.

J Natl Cancer Inst. 2003 Oct 1;95(19):1462-6.

PMID:
14519752
4.

Screening for prostate cancer: estimating the magnitude of overdetection.

McGregor M, Hanley JA, Boivin JF, McLean RG.

CMAJ. 1998 Dec 1;159(11):1368-72.

5.

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH.

Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Review.

PMID:
15780157
6.

MISCAN: estimating lead-time and over-detection by simulation.

Draisma G, De Koning HJ.

BJU Int. 2003 Dec;92 Suppl 2:106-11.

8.
9.

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.

J Natl Cancer Inst. 2002 Jul 3;94(13):981-90.

PMID:
12096083
10.

4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.

Schröder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ.

J Urol. 2005 Aug;174(2):489-94; discussion 493-4.

PMID:
16006878
11.

Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.

Schröder FH, Bangma CH, Roobol MJ.

Eur Urol. 2008 May;53(5):901-8. doi: 10.1016/j.eururo.2008.01.048. Epub 2008 Jan 28.

PMID:
18262712
12.

[Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].

Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.

Prog Urol. 2009 Jul;19(7):487-98. doi: 10.1016/j.purol.2009.03.001. Epub 2009 Apr 28. French.

PMID:
19559380
13.
14.

Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.

Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.

Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17.

PMID:
21601352
16.
17.

Pathologic features of prostate cancer found at population-based screening with a four-year interval.

Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN, Schröder FH.

J Natl Cancer Inst. 2001 Aug 1;93(15):1153-8.

PMID:
11481387
18.
19.

hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.

Raaijmakers R, de Vries SH, Blijenberg BG, Wildhagen MF, Postma R, Bangma CH, Darte C, Schröder FH.

Eur Urol. 2007 Nov;52(5):1358-64. Epub 2007 Apr 20.

PMID:
17499425
20.

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.

Telesca D, Etzioni R, Gulati R.

Biometrics. 2008 Mar;64(1):10-9. Epub 2007 May 14.

PMID:
17501937

Supplemental Content

Support Center